anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to sustained release formulation including a drug release layer and a porous gastric retentive layer and a production method thereof. More specifically, the drug release layer includes a drug and a sustained release agent. The gastric retentive layer has a porous structure and includes a swelling polymer or a non-swelling polymer. The sustained release formulation may be immediately floated at the time of ingestion due to floating force generated by forming pores at the gastric retentive layer so that the gastric retentive layer may always be located at an upper portion in stomach. Therefore, the drug release layer is not exposed to an upper portion of body fluid and drug release can be maintained for a long time. In addition, the sustained release formulation has an advantage in that strength of the formulation is excellent because the formulation includes the swelling polymer or the non-swelling polymer in the gastric retentive layer.
A total of 20 patients with bilateral symmetrical vernal keratoconjunctivitis will be included. Each patient will undergo a complete ophthalmologic evaluation. Patient will be placed at random on topical Tacrolimus 0.01% ophthalmic solution in one eye and placebo eyedrops in the fellow eye. Patients will undergo ophthalmologic examination at one week and after one month. Photos will be taken. The outcome measures include graded symptoms, graded signs, and laboratory investigations. Symptoms of itching, redness, foreign body sensation, tearing and discharge following will be recorded before and after treatment. The grading of clinical signs of conjunctival hyperemia, conjunctival papillary hypertrophy, perilimbal infiltrates, Trantas dots, superficial punctate keratopathy will be recorded before and after treatment. Conjunctival surface temperature will be determined before and after treatment. Conjunctival scrapings will be stained with Giemsa and will be assessed before and after therapy and number of eosinophils per hpf will be determined and recorded.
OBJECTIVES: To evaluate the preventive effects of Saccharomyces boulardii powder and tetragenous viable Bifidobacterium tablets on antibiotic-associated diarrhea (AAD) in infants and young children.
METHODS: Children under three years old admitted to the Department of Pediatrics, Affiliated Hospital of Xuzhou Medical University due to non-gastrointestinal infections and requiring antibiotic treatment from July to December 2023 were enrolled. The children were randomly divided into a control group (n=47), a Saccharomyces boulardii group (n=70), and a Bifidobacterium group (n=65) using a random number table method. The control group received antibiotics and symptomatic supportive treatment according to relevant clinical guidelines. In addition to the treatment given to the control group, the Saccharomyces boulardii group and the Bifidobacterium group were respectively administered with Saccharomyces boulardii powder and tetragenous viable Bifidobacterium tablets. Based on the duration of probiotic use (7 days, 14 days, and 21 days), the Saccharomyces boulardii group was further divided into 7 d, 14 d, and 21 d subgroups, and similarly for the Bifidobacterium group. The incidence of AAD and ratio of cocci to bacilli in feces were compared among the groups after treatment.
RESULTS: The incidence rate of AAD in both the Saccharomyces boulardii group and the Bifidobacterium group was lower than that in the control group (P<0.017). The duration of AAD and the length of hospital stay were shorter in the Saccharomyces boulardii and Bifidobacterium groups compared to the control group (P<0.05). In the control group, the ratio of cocci to bacilli in feces on days 7, 14, and 21 was higher than on day 1 (P<0.05). Within-group comparisons showed that the ratio of cocci to bacilli in feces on day 14 in the Bifidobacterium 14 d and 21 d groups were lower than on day 1 (P<0.05); and the ratios on day 14 in the control group, Saccharomyces boulardii 14 d group, Saccharomyces boulardii 21 d group, Bifidobacterium 14 d group, and Bifidobacterium 21 d group were lower than on day 7 (P<0.05). The ratios on day 21 in the control group and the Saccharomyces boulardii 21 d group were lower than on days 7 and 14 (P<0.05). Between-group comparisons indicated that on day 7, the ratios of cocci to bacilli in feces in the Saccharomyces boulardii 7 d, 14 d, 21 d groups, and Bifidobacterium 7 d, 14 d, 21 d groups were all lower than in the control group (P<0.05); on day 14, the ratios of cocci to bacilli in feces 14 d and 21 d groups were lower than in the control group and the Bifidobacterium 7 d group (P<0.05).
CONCLUSIONS: Both Saccharomyces boulardii and tetragenous viable Bifidobacterium can effectively improve gut microbiota and prevent the occurrence of AAD in infants and young children. Compared to short-term treatment, appropriately extending the duration of probiotic therapy can further improve the structure of gut microbiota.
The invention discloses a novel polypeptide coupled drug compound, a preparation method and application thereof. The structural general formula of the compound is as follows: wherein: r1 and R2 are selected from hydrogen, methyl, methoxy, chlorine, bromine and iodine; n is selected from 0,2,4,6 and 8. The compound utilizes the synergistic effect of the photodynamic sterilization effect of the antibacterial peptide and the photosensitive group to achieve the high-efficiency broad-spectrum antibacterial effect on gram-negative bacteria and gram-positive bacteria, and the MIC can reach at least 62.5nM. Meanwhile, the introduction of the photosensitive group also endows the compound with aggregation-induced luminescence characteristics, and near infrared wash-free imaging of bacteria is realized. The compound has wide application prospect in the aspects of bacterial imaging and bacterial infection resistance. The polypeptide coupled drug compound provided by the invention has the advantages of simple preparation method, cheap and easily available raw materials, simple and convenient synthesis process, easy separation and purification, and suitability for large-scale production and popularization and application.
During the induction phase, participants receive pembrolizumab 200 mg q3w for 4 cycles, carboplatin AUC 6 (mg/mL/min) q3w for 4 cycles, and paclitaxel 200 mg/m2 q3w for 4 cycles or nab-paclitaxel 100 mg/m2 weekly for 4 cycles. During the Maintenance phase, participants receive pembrolizumab 400 mg q6w for 96 weeks.
Glioblastoma multiforme (GBM) patients have a high recurrence rate of 90%, and the 5-year survival rate is only about 5%. Cytosine deaminase (CDA)/5-fluorocytosine (5-FC) gene therapy is a promising glioma treatment as 5-FC can cross the blood-brain barrier (BBB), while 5-fluorouracil (5-FU) cannot. Furthermore, 5-FU can assist reversing the immunological status of cold solid tumors. This study developed mesenchymal stem cells (MSCs) co-expressing yeast CDA and the secretory IL18-FC superkine to prevent recurrent tumor progression by simultaneously exerting cytotoxic effects and enhancing immune responses. IL18 was fused with Igk and IgG2a FC domains to enhance its secretion and serum half-life. The study confirmed the expression and activity of the CDA enzyme, as well as the expression, secretion, and activity of secretory IL18 and IL18-FC superkine, which were expressed by lentiviruses transduced-MSCs. In the transwell tumor-tropism assay, it was observed that the genetically modified MSCs retained their selective tumor-tropism ability following transduction. CDA-expressing MSCs, in the presence of 5-FC (200 µg/ml), induced cell cycle arrest and apoptosis in glioma cells through bystander effects in an indirect transwell co-culture system. They reduced the viability of the direct co-culture system when they constituted only 12.5 % of the cell population. The effectiveness of engineered MSCs in suppressing tumor progression was assessed by intracerebral administration of a lethal dose of GL261 cells combined in a ratio of 1:1 with MSCs expressing CDA, or CDA and sIL18, or CDA and sIL18-FC, into C57BL/6 mice. PET scan showed no conspicuous tumor mass in the MSC-CDA-sIL18-FC group that received 5-FC treatment. The pathological analysis showed that tumor progression suppressed in this group until 20th day after cell inoculation. Cytokine assessment showed that both interferon-gamma (IFN-γ) and interleukin-4 (IL-4) increased in the serum of MSC-CDA-sIL18 and MSC-CDA-sIL18-FC, treated with normal saline (NS) compared to those of the control group. The MSC-CDA-sIL18-FC group that received 5-FC treatment showed reduced serum levels of IL-6 and a considerably improved survival rate compared to the control group. Therefore, MSCs co-expressing yeast CDA and secretory IL18-FC, with tumor tropism capability, may serve as a supplementary approach to standard GBM treatment to effectively inhibit tumor progression and prevent recurrence.
All patients will be allocated to the same arm. All patients will have EBUS TBNA done with both 19-gauge and 21-gauge needles during the procedure.
<P>PROBLEM TO BE SOLVED: To provide a composition for preventing onset of psychiatric disorder, and to provide a method for evaluating the possibility of the onset of the psychiatric disorder.  <P>SOLUTION: The composition contains an unsaturated fatty acid or an oil and fat containing at least one unsaturated fatty acid as a constituent fatty acid. The composition is regulated so as to be fed to the body at an immature stage of the brain tissue. The possibility of the onset of the psychiatric disorder by individual is evaluated based on a bonding strength by amplifying Fabp7 gene by using a genome DNA isolated from the individual as a template, and measuring the bonding strength between the polypeptide encoded by the Fabp7 gene and the unsaturated fatty acid. In another embodiment, the possibility of the onset of the psychiatric disorder by the individual is evaluated based on a base sequence by determining the base sequence of the Fabp7 gene on the genome DNA isolated from the individual.  <P>COPYRIGHT: (C)2009,JPO&INPIT
The use of self-collected specimens as an alternative to healthcare worker-collected specimens for diagnostic testing has gained increasing attention in recent years. This systematic review aimed to assess the diagnostic accuracy of self-collected specimens compared to healthcare worker-collected specimens across different sexually transmitted infections (STIs) including Chlamydia trachomatis (CT), human papillomavirus (HPV), Mycoplasma genitalium (MG), Neisseria gonorrhoea (NG), Treponema pallidum and Trichomonas vaginalis (TV) in females. A rigorous process was followed to screen for studies in various electronic databases. The quality of included studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 tool. There were no studies on syphilis that met the criteria for inclusion in the review. A total of six studies for chlamydia, five studies for HPV, four studies for MG, and seven studies for gonorrhoea and trichomoniasis were included in the review. However, not all studies were included in the sub-group meta-analysis. The analysis revealed that self-collected specimens demonstrated comparable diagnostic accuracy to healthcare worker-collected specimens across most STIs. This indicates that the diagnostic accuracy of self-collected specimens can provide accurate results and enhance access to diagnostic testing, potentially improving healthcare service delivery. Future research should further explore the diagnostic accuracy of self-collected specimens in larger and more diverse populations.
The invention discloses a safe and environment-friendly oil-tea camellia extract mosquito repellent with functions of resisting inflammation, eliminating swelling and relieving itching. The mosquito repellent is prepared from, by weight, 90-99 parts of oil-tea camellia extracts, 0-9 parts of water and 0-2 parts of food-grade preservative. The oil-tea camellia extracts are any one or more of tea-oil tree branch extracts, tea-oil tree leaf extracts and tea-oil tree fruit shell extracts. The oil-tea camellia extracts are any one or more of extracts obtained through the solid-phase extraction method, extracts obtained through the steam distillation extraction method and extracts obtained through the supercritical fluid extraction method. The oil-tea camellia extract mosquito repellent is rich in various aldehydes, has a good acting effect and is rapid in acting speed and free of pollution to the environment. Rich tea polyphenol can effectively remove peroxy radicals, and the mosquito repellent has good effects of resisting inflammation, eliminating swelling and relieving itching and is free of irritation to human bodies and safe and reliable to use.
Described is the identification of a receptor for a satiety factor, which is involved in body weight homeostasis. Mutations in this receptor are associated with obese phenotypes. In particular, the identification and characterization of the receptor for leptin, including a naturally occurring soluble form of the receptor is described. The receptor is expected to modulate leptin activity, in particular to agonise leptin activity. Further described are nucleic acids encoding the receptor, and methods for using the receptor, e.g., to identify leptin analogues, therapeutically, such as in gene therapy or in soluble form as an agonist or antagonist of leptin activity. (62) Divided out of 330972
Since the last twenty years, thousands of babies were born from infertile couples treated in our center. However, the short, and especially the long term prognosis of these children were barely known.

Since last decade, Clinical Reproductive Medicine Management System/Electronic Medical Record Cohort Database (CCRM/EMRCD) has been used in Reproductive Medical Center, First Affiliated Hospital of Zhengzhou University, and Henan Province Key Laboratory for Reproduction and Genetics. Information of patients (POI, PCOS, Endometriosis, azoospermia, ect) were recorded comprehensively. In addition, information of each newborn from our center has also been kept in CCRM/EMRCD. The current project plans to recruit these newborn babies in our center. Biological samples, questionnaires and short/long term health data will be collected. The study is aimed to provide evidence for Newborns from patients treated with ART prognosis.
The investigators' ESBR-m intervention consists of four, 90-minute group (= 5 participants) sessions. These four sessions are supplemented with a booster session one month following the last intervention session.
BACKGROUND: Avascular necrosis (AVN) remains the most dreaded complication of unstable slipped capital femoral epiphysis (SCFE) treatment. Newer closed reduction techniques (with perfusion monitoring) have emerged as a technically straightforward means to address residual SCFE deformity while still minimizing the risk of osteonecrosis. However, limited data exists regarding the reliability of intraoperative epiphyseal perfusion monitoring to predict the development of AVN. The purpose of this study was to evaluate its reliability.
METHODS: We retrospectively reviewed all patients with unstable SCFE who underwent closed or open reduction with epiphyseal perfusion monitoring using an intracranial pressure (ICP) probe from 2015 to 2023 at a single institution with a minimum 6-month radiographic follow-up. Demographic, clinical, and radiographic data were recorded, including duration of symptoms, type of reduction, capsulotomy performed, presence of a waveform on ICP monitoring after epiphyseal fixation, and development of AVN on follow-up radiographs.
RESULTS: Our cohort included 33 hips (32 patients), of which 60.6% (n=20) were male. The average age was 12.5±1.8 years, with a median follow-up of 15.8 months. Eleven hips were treated with open reduction using the modified Dunn technique (10 hips) or anterior approach (1 hip), and 22 hips were treated with inadvertent (5 hips) or purposeful closed reduction using the Leadbetter technique (17 hips). Overall, 8 of the 33 hips in our series (24.2%) developed AVN, 6 of which (20%) had a pulsatile waveform on intraoperative epiphyseal perfusion monitoring. The overall rate of AVN after closed reductions was 31.8% (7 of 22 hips); the incidence of AVN after closed reduction with a detectable waveform was 30% (6 of 20 hips). There was no significant association between time to surgery ( P =0.416) or type of reduction ( P =0.218) and the incidence of AVN.
CONCLUSIONS: In this series, intraoperative epiphyseal perfusion monitoring did not reliably predict the development of osteonecrosis. To our knowledge, this is the first study to report AVN after demonstrable intraoperative epiphyseal perfusion following closed reduction of unstable slips.
LEVEL OF EVIDENCE: Level IV: case series-therapeutic study.
The invention provides a phloroglucinol film-coated tablet with an antioxidative function and a preparation method thereof. Phloroglucinol dihydrate is used as an active ingredient, excipients such as a filling agent, an antioxidant and a lubricating agent are added into the active ingredient, and coating with a water-soluble coating material to prepare the phloroglucinol film-coated tablet. The preparation method comprises the following steps of sieving, mixing, pelletizing, tabletting and coating. The phloroglucinol film-coated tablet can effectively overcome the easy-oxidization performance of phloroglucinol, the labeled amount can be controlled, the tablet weight variation is stable, and the dissolution speed is high. The stability is good after the phloroglucinol is coated, the rate of finished products is high, and the cost is low. The preparation method is simple to operate and easy to master and regulate, and the quality of products is stable and controllable.
The retinal degeneration (rdl) mutant mouse exhibits rapid rod photoreceptor degeneration caused by a mutation in the rod photoreceptor-specific gene cGMP phosphodiesterase β (PDE). One intriguing aspect of the rdl phenotype is a secondary wave of cone photoreceptor death that follows loss of rods. In this study, we investigated gene expression changes associated with the progression of photoreceptor degeneration in rdl mice using a custom retina microarray. The microarray contains 5,376 DNA fragments that correspond to mouse genes known or postulated to be involved in normal retinal function, development, or disease. Gene expression in rdl retina was compared with age-matched wild-type controls at three time-points corresponding to critical stages in retina degeneration: peak of rod degeneration, early in cone degeneration and during cone degeneration. Statistical significance analyses demonstrated that approximately 3% of the genes on the microarray were differentially expressed, including known genes and genes that had not been previously implicated in degeneration. Interestingly, there was less overlap in the genes that were upregulated at each stage of degeneration, suggesting the involvement of distinct molecular pathways. Genes involved in transport, signalling and cytoskeleton were differentially expressed during rod degeneration whereas genes involved in growth and proliferation, oxidative stress and protein modification were increased prior to and during cone degeneration. These results provide clues to underlying molecular processes occurring during photoreceptor degeneration, and provide direction for future cell-based studies.
Participants received Cyclophosphamide and VELCADE at Level 4 (the MPD) at the same schedule of the Phase I study. Pegylated doxorubicin and Dexamethasone were given at the same doses and schedule as the Phase I part of study.
The invention discloses a traditional Chinese medicine cuttlebone and bletilla rhizome powder for treatment of peptic ulcer, and mainly helps to solve problems of existing medicaments for treatment of peptic ulcer that: curative effect is low and side-effects exist. The powder is produced by following steps: taking 30 portions of cuttlebone, 20 portions of Zhejiang fritillaria bulb and 30 portions of bletilla rhizome; grinding the ingredients above into fine powder together; storing the powder in bottles. Dosage and administration are that: 6g each time, and 4 times a day. The powder is taken with water 30min before meals. Each treatment course takes 21 days, and the powder can be taken continuously for 3 treatment courses. Effective rate for treatment of gastric ulcer is 95% or more, cure rate is 80% or more. The powder has no toxic or side effects.
INTRODUCTION: Placental dysfunction is the primary cause of selective fetal growth restriction (sFGR), and the specific role of mitochondria remains unclear. This study aims to elucidate mitochondrial functional defects in sFGR placentas and explore the roles of mitochondrial genomic and epigenetic alterations in its pathogenesis.
METHODS: The placental villi of MCDA twins with sFGR were collected and the morphology and number of mitochondria were observed by transmission electron microscopy. Meanwhile, the levels of reactive oxygen species (ROS), ATP and oxidative damage markers were assessed. Mitochondrial DNA (mtDNA) copy number detection, targeted sequencing and methylation sequencing were performed. The expression of placental cytochrome c oxidase subunit I (COX I) and mitochondrial long non-coding RNAs (lncRNAs) were evaluated by Western blotting and qPCR.
RESULTS: Compared with placentae from normal fetuses, pronounced mitochondrial damage within cytotrophoblast was revealed in sFGR placentae, alongside augmented mitochondrial number in syncytiotrophoblast. Enhanced oxidative stress in these placentae was evidenced by elevated markers of oxidative damage, accompanied by increased ROS production and diminished ATP generation. In sFGR placentae, a notable rise in mitochondrial copy number and one heterozygous mutation in the MT-RNR2 gene were observed, along with decreased COX Ⅰ levels, increased lncND5, lncND6, lncCyt b, and MDL1 synthesis, and decreased RMRP synthesis.
DISCUSSION: Findings collectively confirmed an exacerbation of oxidative stress within sFGR placentae, coinciding with mitochondrial dysfunction, compromised energy production, and ultimately the failure of compensatory mechanisms to restore energy balance, which may result from mutations in the mitochondrial genome and abnormal expression of epigenetic regulatory genes.
Dextroamphetamine sulfate is the dextro isomer of the compound d,l -amphetamine sulfate, a sympathomimetic amine of the amphetamine group. Chemically, dextroamphetamine is d-alpha-methylphenethylamine, and is present in all forms of dextroamphetamine as the neutral sulfate. The structural formula is as follows:

(C9H13N)2 • H2SO4  Molecular Weight: 368.49

Each extended-release capsule is so prepared that an initial dose is released promptly and the remaining medication is released gradually over a prolonged period.

Each capsule contains dextroamphetamine sulfate, and has the following inactive ingredients: colloidal silicon dioxide, dibutyl sebacate, ethylcellulose aqueous dispersion, methylcellulose, povidone, propylene glycol, sugar spheres and talc.

The capsule shell ingredients in the 5 mg are D&C red no. 33, FD&C blue no. 1, FD&C yellow no. 6, gelatin, and titanium dioxide.

The capsule shell ingredients in the 10 mg are black iron oxide, gelatin, red iron oxide, titanium dioxide, and yellow iron oxide.

The capsule shell ingredients in the 15 mg are black iron oxide, gelatin, red iron oxide, titanium dioxide, and yellow iron oxide.

The imprinting ingredients are D&C yellow no. 10 aluminum lake, FD&C blue no. 1 aluminum lake, FD&C blue no. 2 aluminum lake, FD&C red no. 40 aluminum lake, pharmaceutical glaze, propylene glycol, and synthetic black iron oxide.
Participants will receive PA-824 on Days 1 to 7, no study medication on Days 8 to 21, EFV on Days 22 to 35, and EFV plus PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 7, 34, and 41 to 42.